-
Mashup Score: 1Paper: Immune Profiling Reveals Distinct Features of Multiple Myeloma Subtypes Defined By Multi-Omics Network Analysis - 1 day(s) ago
Program: Oral and Poster Abstract s Session: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster III Hematology Disease Topics & Pathways: Research, Translational Research, Genomics, Immunology, Biological Processes Junia Vieira, MD, PhD 1 *, Alison S Park, BSc 2 *, Edgar Gonzalez-Kozlova, PhD 3 *, David Melnekoff, PhD 1 *, Sherry Bhalla, PhD 4 *, Chaitanya Acharya, PhD 5 *, Mark Hamilton, MD 6, George Mulligan, PhD 6, Immune Atlas Network 7 *, Hearn Jay Cho, MD, PhD 8, Li
Source: ash.confex.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1
Program: Oral and Poster Abstracts Session: 653. Multiple Myeloma: Clinical and Epidemiological: Poster I Hematology Disease Topics & Pathways: Research, Clinical trials, Translational Research, Clinical Research, Measurable Residual Disease Benjamin A Derman, MD 1, Tadeusz Kubicki 2 *, Jennifer H Cooperrider, MD 1, Anna Pula 2 *, Ken Jiang 2 *, Mariel Coradin 3 *, Ravleen Virdi, MSc 3 *, Fionn McLoughlin, PhD 3 *, Luciano Di Stefano, PhD 4 *, Vincent Bonifay, PhD 5 *, Caroline Rougé Dubroc, PharmD 4 *
Source: ash.confex.comCategories: General Medicine News, Partners & KOLsTweet-
RT @Taxkourel: https://t.co/AkVUfMKPoD A taste of clonotypic MS (peripheral blood) to identify MRD instead of bone marrow biopsies by @bder…
-
-
Mashup Score: 16Paper: 24-Hour Urine Testing Does Not Add Value to Multiple Myeloma Response Assessments: A Secondary Analysis of BMT CTN 0702 - 1 day(s) ago
Program: Oral and Poster Abstracts Type: Oral Session: 653. Multiple Myeloma: Clinical and Epidemiological: Decluttering Responses and Dynamic Risk: How Can We Improve Prognostication in Multiple Myeloma? Hematology Disease Topics & Pathways: Research, Clinical trials, Clinical Practice (Health Services and Quality), Clinical Research, Health outcomes research, Plasma Cell Disorders, Diseases, Lymphoid Malignancies 1 University of Washington Fred Hutchinson Cancer Center, Seattle, WA 2 University of
Source: ash.confex.comCategories: General Medicine News, Partners & KOLsTweet-
4/ #ASH24 Abstract 81 (Banerjee) [COI: I'm very passionate about this!] Urine-free IMWG response criteria (without 24-hr urines in fridge) worked just fine in @BMTCTN 0702. ⬇️ pt discomfort, ⬇️ #MMsm study deviations. The p-value of pee is minimal! https://t.co/O4oWoHsswO https://t.co/QFS3BIXn8y https://t.co/bqWIIxZj3E
-
-
Mashup Score: 8Paper: Eliminating the Need for Sequential Confirmation of Response in Multiple Myeloma - 1 day(s) ago
Program: Oral and Poster Abstracts Type: Oral Session: 653. Multiple Myeloma: Clinical and Epidemiological: Decluttering Responses and Dynamic Risk: How Can We Improve Prognostication in Multiple Myeloma? Hematology Disease Topics & Pathways: Plasma Cell Disorders, Education, Diseases, Lymphoid Malignancies, Human 1 Division of Hematology, Mayo Clinic, Rochester, MN 2 Hôpital Maisonneuve-Rosemont, Université de Montréal, Hematology-Oncology and Cell Therapy University Institute, Montreal, QC, Canada 3
Source: ash.confex.comCategories: General Medicine News, Partners & KOLsTweet-
3/ #ASH24 Abstract 83 (Claveau) Q: Well if MRD-P is PD, what isn’t PD in #MMsm? A: Waiting for a confirmatory set of labs... 98% of the time, single PD timepoint is sufficient. Asking pt to return for extra labs means more #timetoxicity and no benefit. https://t.co/4jlDFONB6U https://t.co/n0pHde7L85 https://t.co/psH4Zc5P3C
-
-
Mashup Score: 12Paper: Reevaluating the IMWG Multiple Myeloma Complete Response Criterion in the Era of Mass Spectrometry: A Critical Analysis - 1 day(s) ago
Program: Oral and Poster Abstracts Type: Oral Session: 653. Multiple Myeloma: Clinical and Epidemiological: Cellular and Molecular Profiling of Multiple Myeloma: Implications for Clinical Practice Hematology Disease Topics & Pathways: Measurable Residual Disease Noemi Puig, PhD 1,2, Cristina Agullo 2 *, Bruno Paiva, PhD 3,4,5,6 *, María T Cedena 7 *, Laura Rosiñol Dachs 8,9,10 *, Teresa Contreras 11 *, Joaquín Martínez-Lopez 12,13 *, Albert Oriol 14,15 *, María-Jesús Blanchard, MD, PhD 16,17 *, Rafael
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
#ASH24 Reevaluating the IMWG MM CR Criteria with Mass Spectrometry (MS) -MS surpasses the clinical value of BM PC% and sIFE -Study suggests that BM aspirate is only needed for MRD assessment #mmsm #bmtsm @NoemiPuig2 @mvmateos @BrunoPaiva_UNAV https://t.co/CTUMNyiJtu
-
-
Mashup Score: 1
Program: Oral and Poster Abstracts Type: Oral Session: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Resistance and Response to Anti-Myeloma Therapies Hematology Disease Topics & Pathways: Research, Translational Research, Plasma Cell Disorders, Diseases, Lymphoid Malignancies, Technology and Procedures, Imaging, Omics technologies 1 Harvard Medical School, Boston, MA 2 Dana-Farber Cancer Institute, Brookline, MA 3 Broad Institute of MIT and Harvard, Cambridge, MA 4 Dana-
Source: ash.confex.comCategories: General Medicine News, Partners & KOLsTweet-
RT @Taxkourel: https://t.co/ahhZFsFulB by @IrenemGhobrial spatially defined “bad players” (MDSCs, M2 macrophages, exhausted T cells) predic…
-
-
Mashup Score: 3
Program: Oral and Poster Abstracts Session: 907. Outcomes Research: Plasma Cell Disorders: Poster II Hematology Disease Topics & Pathways: Research, Adult, Clinical Research, Health outcomes research, Plasma Cell Disorders, Diseases, Lymphoid Malignancies, Study Population, Human Kathy Annunziata 1 *, Nikoletta Sternbach 1 *, Hitomi Tanaka 2 *, Marco DiBonaventura 2 *, Joseph C. Cappelleri, PhD 3 *, Jack Watkins 2 *, David Hughes, PharmD 4, Aster Meche 2 *, Chai Hyun Kim 2 *, C. Todd Kennedy 5 *, Hans
Source: ash.confex.comCategories: General Medicine News, Partners & KOLsTweet-
RT @Taxkourel: https://t.co/gkh8LKa5T4 Impact of #myeloma on the unsung heroes of this disease: the caregivers #ASH24
-
-
Mashup Score: 23
Program: Oral and Poster Abstracts Type: Oral Session: 653. Multiple Myeloma: Clinical and Epidemiological: Addressing Hematologic and Immune Toxicities and the Status of Quad Therapies Hematology Disease Topics & Pathways: Clinical Practice (Health Services and Quality) Heloise Cheruvalath 1, Anna Clennon 2 *, Asis Shrestha, MD 3 *, Aniko Szabo, PhD 1 *, Vineel Bhatlapenumarthi, MD 4 *, Anannya Patwari, MD 1 *, Metodi Balev 5 *, Divaya Bhutani, MD 6, Sharmilan Thanendrarajan, MD 7, Binod Dhakal, MBBS 8,
Source: ash.confex.comCategories: General Medicine News, Partners & KOLsTweet-
9/ #ASH24 Abstract 256 (Cheruvalath) Preemptive strategy #2 to make BCMA bsAbs safer in #MMsm Don't wait until IgG < 400 (this is myeloma, not rheumatology)... give IVIG now! Or even start IVIG right before bsAb starts... both better than waiting! https://t.co/MZD4Pe9Pwz https://t.co/GrFJktKqPe https://t.co/Qf0rkR4Mq0
-
-
Mashup Score: 4
Program: Oral and Poster Abstracts Type: Oral Session: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Microenvironment and Immunity in Myeloma Hematology Disease Topics & Pathways: Research, Clinical trials, Adult, Translational Research, Clinical Research, Plasma Cell Disorders, Supportive Care, Diseases, Immune mechanism, Treatment Considerations, Lymphoid Malignancies, Biological Processes, Microbiome, Study Population, Human, Animal model Urvi A. Shah, MD 1,2, Laura Lucia
Source: ash.confex.comCategories: General Medicine News, Partners & KOLsTweet-
RT @Taxkourel: SUPPORTIVE CARE/QOL 1. https://t.co/hbdwoDWpZ0 By @UrviShahMD: high fiber diet improved metabolic, microbiome and immune pro…
-
-
Mashup Score: 3Paper: Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium - 1 day(s) ago
Program: Oral and Poster Abstracts Session: 907. Outcomes Research: Plasma Cell Disorders: Poster II Hematology Disease Topics & Pathways: Research, Clinical Research, Plasma Cell Disorders, Supportive Care, Diseases, Real-world evidence, Treatment Considerations, Lymphoid Malignancies 1 University of Washington Fred Hutchinson Cancer Center, Seattle, WA 2 Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL 3 Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland
Source: ash.confex.comCategories: General Medicine News, Partners & KOLsTweet-
Thanks @MarkGeyerMD for noticing this! I’m excited to see USPI - will obe-cel also not come with the 8 weeks of driving restrictions that all other CAR-T products have had? (Our #ASH24 abstract shows why this is unnecessary in #MMsm, for instance) https://t.co/1a0UwfiITP
-
RT @Taxkourel: https://t.co/e545T72QSq By @alagana1 and @theMMRF Immune Atlas : t(11;14) patients have a healthier T cell pool which may ma…